The TAA WT1 has also been exploited as a target for mesothelioma vaccine therapy [80], and the efficacy of a combined approach composed by a WT1-specific peptide vaccine (Galinpepimut-S, GPS) and the anti-PD-1 mAb Nivolumab has recently been evaluated in a phase I trial in mesothelioma patients with WT1-positive tumors [46]. This evidence concerns the gene PDCD1 and mesothelioma.